Salute e Benessere
Interim report Q2/2024: Enzymatica builds momentum for expansion
"Many factors now point to a favorable pathway for Enzymatica. We are making great strides in research, we have received the MDR certification, we are garnering international interest and we are seeing signs of regulatory developments that could be beneficial to us. At the same time, we need to expand our partner network, which does not happen overnight. Registrations in new countries will delay the launch in the largest international markets and we want to increase our research efforts.
The board's decision to update the financial goals and acquire more capital for the company gives us the peace of mind and long-term perspective required to build momentum in the autumn together with existing and new partners and then achieve the strong sales growth that we have planned for several years. I am convinced that the world will see a strong and successful Enzymatica rise in the next few years", said Claus Egstrand, CEO.
Significant events during the quarter
Significant events after the quarter
Other events during and after the quarter
The full report is available on: www.enzymatica.com/investors/financial-reports
For more information, please contact:
Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/enzymatica-ab/r/interim-report-q2-2024-enzymatica-builds-momentum-for-expansion,c4016269
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/interim-report-q22024-enzymatica-builds-momentum-for-expansion-302200408.html